港股異動 | 康希諾生物-B漲逾7% 科創板首發4月30日上會
格隆匯4月23日丨港股市場“疫苗第一股”康希諾生物-B(6185.HK)自去年3月28日於港交所上市後股價持續上漲,截至去年年底累漲93.28%。今年以來,該股受新冠肺炎病毒疫苗等相關利好影響,股價繼續大漲,並於4月6日盤中高見161港元創上市新高。後因主要股東高位減持、年度淨虧損擴大至1.57億元(人民幣,下同)等因素,股價7個交易日回調約25%。不過,該股本週已反彈超25%,回補此前全部跌幅,現報158.6港元,漲7.89%,暫成交8306萬港元,最新總市值353億港元。上交所昨日發佈科創板上市委2020年第21次審議會議公告稱,康希諾生物股份公司首發4月30日上會。上會稿招股説明書當中載有今年一季度業績,期內實現營收403萬元,同比增長605.10%;歸屬於母公司股東的淨虧損2310.3萬元,同比收窄48.94%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.